TY - JOUR
T1 - Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis
AU - De Jong, Petrus R.
AU - Takahashi, Naoki
AU - Harris, Alexandra R.
AU - Lee, Jihyung
AU - Bertin, Samuel
AU - Jeffries, James
AU - Jung, Michael
AU - Duong, Jen
AU - Triano, Amy I.
AU - Lee, Jongdae
AU - Niv, Yaron
AU - Herdman, David S.
AU - Taniguchi, Koji
AU - Kim, Chang Whan
AU - Dong, Hui
AU - Eckmann, Lars
AU - Stanford, Stephanie M.
AU - Bottini, Nunzio
AU - Corr, Maripat
AU - Raz, Eyal
PY - 2014/9/2
Y1 - 2014/9/2
N2 - The intestinal epithelium has a high rate of turnover, and dysregulation of pathways that regulate regeneration can lead to tumor development; however, the negative regulators of oncogenic events in the intestinal epithelium are not fully understood. Here we identified a feedback loop between the epidermal growth factor receptor (EGFR), a known mediator of proliferation, and the transient receptor potential cation channel, subfamily V, member 1 (TRPV1), in intestinal epithelial cells (IECs). We found that TRPV1 was expressed by IECs and was intrinsically activated upon EGFR stimulation. Subsequently, TRPV1 activation inhibited EGFR-induced epithelial cell proliferation via activation of Ca2+/calpain and resulting activation of protein tyrosine phosphatase 1B (PTP1B). In a murine model of multiple intestinal neoplasia (ApcMin/+mice), TRPV1 deficiency increased adenoma formation, and treatment of these animals with an EGFR kinase inhibitor reversed protumorigenic phenotypes, supporting a functional association between TRPV1 and EGFR signaling in IECs. Administration of a TRPV1 agonist suppressed intestinal tumorigenesis in ApcMin/+mice, similar to - as well as in conjunction with - a cyclooxygenase-2 (COX-2) inhibitor, which suggests that targeting both TRPV1 and COX-2 has potential as a therapeutic approach for tumor prevention. Our findings implicate TRPV1 as a regulator of growth factor signaling in the intestinal epithelium through activation of PTP1B and subsequent suppression of intestinal tumorigenesis.
AB - The intestinal epithelium has a high rate of turnover, and dysregulation of pathways that regulate regeneration can lead to tumor development; however, the negative regulators of oncogenic events in the intestinal epithelium are not fully understood. Here we identified a feedback loop between the epidermal growth factor receptor (EGFR), a known mediator of proliferation, and the transient receptor potential cation channel, subfamily V, member 1 (TRPV1), in intestinal epithelial cells (IECs). We found that TRPV1 was expressed by IECs and was intrinsically activated upon EGFR stimulation. Subsequently, TRPV1 activation inhibited EGFR-induced epithelial cell proliferation via activation of Ca2+/calpain and resulting activation of protein tyrosine phosphatase 1B (PTP1B). In a murine model of multiple intestinal neoplasia (ApcMin/+mice), TRPV1 deficiency increased adenoma formation, and treatment of these animals with an EGFR kinase inhibitor reversed protumorigenic phenotypes, supporting a functional association between TRPV1 and EGFR signaling in IECs. Administration of a TRPV1 agonist suppressed intestinal tumorigenesis in ApcMin/+mice, similar to - as well as in conjunction with - a cyclooxygenase-2 (COX-2) inhibitor, which suggests that targeting both TRPV1 and COX-2 has potential as a therapeutic approach for tumor prevention. Our findings implicate TRPV1 as a regulator of growth factor signaling in the intestinal epithelium through activation of PTP1B and subsequent suppression of intestinal tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=84907007750&partnerID=8YFLogxK
U2 - 10.1172/JCI72340
DO - 10.1172/JCI72340
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25083990
AN - SCOPUS:84907007750
SN - 0021-9738
VL - 124
SP - 3793
EP - 3806
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 9
ER -